IL319156A - Controlled-release oral dosage forms are resistant to gastric acid. - Google Patents

Controlled-release oral dosage forms are resistant to gastric acid.

Info

Publication number
IL319156A
IL319156A IL319156A IL31915625A IL319156A IL 319156 A IL319156 A IL 319156A IL 319156 A IL319156 A IL 319156A IL 31915625 A IL31915625 A IL 31915625A IL 319156 A IL319156 A IL 319156A
Authority
IL
Israel
Prior art keywords
gastro
dosage forms
controlled release
oral dosage
release oral
Prior art date
Application number
IL319156A
Other languages
English (en)
Hebrew (he)
Original Assignee
Minerva Neurosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62904624&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL319156(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Minerva Neurosciences Inc filed Critical Minerva Neurosciences Inc
Publication of IL319156A publication Critical patent/IL319156A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL319156A 2017-06-21 2018-06-21 Controlled-release oral dosage forms are resistant to gastric acid. IL319156A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762523204P 2017-06-21 2017-06-21
PCT/US2018/038853 WO2018237207A1 (en) 2017-06-21 2018-06-21 GESTRO-RESISTANT ORAL DOSAGE FORMS WITH CONTROLLED RELEASE

Publications (1)

Publication Number Publication Date
IL319156A true IL319156A (en) 2025-04-01

Family

ID=62904624

Family Applications (3)

Application Number Title Priority Date Filing Date
IL319156A IL319156A (en) 2017-06-21 2018-06-21 Controlled-release oral dosage forms are resistant to gastric acid.
IL271606A IL271606B2 (en) 2017-06-21 2018-06-21 Gastro-resistant controlled release oral dosage forms
IL308650A IL308650B2 (en) 2017-06-21 2018-06-21 Gastro-resistant controlled release oral dosage forms

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL271606A IL271606B2 (en) 2017-06-21 2018-06-21 Gastro-resistant controlled release oral dosage forms
IL308650A IL308650B2 (en) 2017-06-21 2018-06-21 Gastro-resistant controlled release oral dosage forms

Country Status (16)

Country Link
US (3) US11464744B2 (https=)
EP (1) EP3641732A1 (https=)
JP (3) JP2020525436A (https=)
CN (1) CN111511353A (https=)
AU (2) AU2018290287B2 (https=)
BR (1) BR112019027398A2 (https=)
CA (1) CA3067031A1 (https=)
CL (1) CL2019003743A1 (https=)
CO (1) CO2019014496A2 (https=)
IL (3) IL319156A (https=)
MX (1) MX2023002994A (https=)
NZ (1) NZ760127A (https=)
PE (1) PE20200732A1 (https=)
UA (1) UA127349C2 (https=)
WO (1) WO2018237207A1 (https=)
ZA (1) ZA202409847B (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3227273T3 (pl) 2014-12-02 2022-05-30 Minerva Neurosciences, Inc. Kompozycje zawierające 2-((1-(2-(4-fluorofenylo)-2-oksoetylo)piperydyn-4-ylo)metylo)izoindolin-1-on do leczenia schizofrenii
IL319156A (en) 2017-06-21 2025-04-01 Minerva Neurosciences Inc Controlled-release oral dosage forms are resistant to gastric acid.
EP3840835A1 (en) 2018-08-21 2021-06-30 Minerva Neurosciences, Inc. Use of roluperidone to treat negative symptoms and disorders, increase neuroplasticity, and promote neuroprotection
IT201800011125A1 (it) * 2018-12-14 2020-06-14 Dpl Pharma S P A Composizioni farmaceutiche orali solide comprendenti matrici monolitiche complesse per la somministrazione cronotropica di medicamenti nel tratto gastroenterico
EP4479049B1 (en) 2022-02-14 2025-12-17 Minerva Neurosciences, Inc. Use of roluperidone in preventing relapse in schizophrenia patients
WO2025090588A1 (en) 2023-10-24 2025-05-01 Minerva Neurosciences, Inc. Roluperidone for the treatment of lysosomal storage disorders and their symptoms

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3888340T2 (de) 1988-01-21 1994-06-30 Merrell Dow Pharma Verwendung von 1,4-disubstituierten-Piperidinyl-Verbindungen zur Herstellung eines Arzneimittels zur Behandlung von Schlaflosigkeit.
ZA908641B (en) 1989-10-27 1992-06-24 Du Pont (n-phthalimidoalkyl)piperidines
CA2134077C (en) 1992-04-23 2002-05-21 Thaddeus R. Nieduzak 4-imidomethyl-1-[2'phenyl-2'oxoethyl-]piperidines as serotonin 5ht2-antagonists, their preparation and use in therapy
US7166617B2 (en) 2000-02-29 2007-01-23 Mitsubishi Pharma Corporation Cyclic amide derivatives
ATE361060T1 (de) 2000-09-29 2007-05-15 Solvay Pharm Bv Ionenstärkenunabhängige pharmazeutische formulierung mit verzögerter freisetzung
ES2405404T3 (es) 2003-10-29 2013-05-31 Wyeth Llc Composiciones farmacéuticas de liberación sostenida que comprenden aplindore y sus derivados
MY147202A (en) * 2003-11-26 2012-11-14 Novartis Ag Compositions comprising organic compounds
TW200616608A (en) 2004-07-09 2006-06-01 Forest Laboratories Memantine as adjunctive treatment to atypical antipsychotics in schizophrenia patients
PE20061490A1 (es) 2005-06-06 2007-02-09 Merck Sharp & Dohme Derivados de ciclohexanosulfonilo como inhibidores del transportador de glicina glyt1
US20090088449A1 (en) 2006-02-07 2009-04-02 Mitsubishi Tanabe Pharma Corporation 4-acylaminopyridine derivative mediated neurogenesis
CA2569776A1 (en) 2006-02-17 2007-08-17 Kos Life Sciences, Inc. Low flush niacin formulation
TW200817400A (en) 2006-05-30 2008-04-16 Elbion Ag Pyrido [3,2-e] pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them
KR20080089279A (ko) 2007-03-30 2008-10-06 미쓰비시 타나베 파마 코퍼레이션 우울증의 예방 및/또는 치료제
GB2462611A (en) 2008-08-12 2010-02-17 Cambridge Lab Pharmaceutical composition comprising tetrabenazine
EP2246331A1 (en) 2009-04-24 2010-11-03 Westfälische Wilhelms-Universität Münster NR2B-selective NMDA-receptor antagonists
ES2530049T3 (es) 2009-05-18 2015-02-26 Sigmoid Pharma Limited Composición que comprende gotas de aceite
AR081935A1 (es) 2010-06-16 2012-10-31 Teijin Pharma Ltd Tableta con nucleo recubierto de liberacion controlada
US8937900B2 (en) 2010-07-20 2015-01-20 Qualcomm Incorporated Enhancing pilot channel transmission in TD-SCDMA multicarrier systems using secondary carrier frequencies
TWI520949B (zh) 2010-07-20 2016-02-11 錫蘭尼克藥物有限公司 使用環醯胺衍生物治療σ受體介導之病症的方法
RS64819B1 (sr) 2010-07-20 2023-12-29 Minerva Neurosciences Inc Metode upotrebe derivata cikličnih amida za lečenje šizofrenije i njenih simptoma
US20120040008A1 (en) 2010-08-11 2012-02-16 Ashish Chatterji Pharmaceutical compositions of metabotropic glutamate 5 receptor (mglu5) antagonists
EP2468264A1 (en) * 2010-12-27 2012-06-27 Laboratorios Liconsa, S.A. Oral pharmaceutical tablet for controled release of mesalazine and process for obtaining it
US9737531B2 (en) 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
KR20140045925A (ko) 2011-03-17 2014-04-17 루핀 리미티드 선택적 세로토닌 재흡수 억제제의 방출조절형 약제학적 조성물
CA2845228C (en) * 2011-08-16 2021-08-10 Baker Idi Heart & Diabetes Institute Holdings Limited Oral controlled-release formulation of 5-(pyridinyl)-2(1h)-pyridinone compounds
AU2014239883B2 (en) * 2013-03-14 2019-01-17 Therabiome, Llc Targeted gastrointestinal tract delivery of probiotic organisms and/or therapeutic agents
CN104586771B (zh) * 2013-10-30 2018-01-16 广州朗圣药业有限公司 一种盐酸坦洛新缓释微丸制剂
MA39987A (fr) * 2014-04-30 2017-03-08 Incyte Corp Procédés de préparation d'un inhibiteur de jak1 et nouvelles formes associées
EP3144308B1 (en) 2014-05-16 2020-06-24 Takeda Pharmaceutical Company Limited Nitrogen-containing heterocyclic compound
WO2015191554A1 (en) 2014-06-09 2015-12-17 Intra-Cellular Therapies, Inc. Compounds and methods of use to treat schizophrenia
KR102425303B1 (ko) * 2014-08-13 2022-07-25 세다르스-신나이 메디칼 센터 항-메탄생성 조성물 및 그것의 용도
PL3227273T3 (pl) 2014-12-02 2022-05-30 Minerva Neurosciences, Inc. Kompozycje zawierające 2-((1-(2-(4-fluorofenylo)-2-oksoetylo)piperydyn-4-ylo)metylo)izoindolin-1-on do leczenia schizofrenii
WO2017066134A1 (en) * 2015-10-16 2017-04-20 Merck Sharp & Dohme Corp. Processes for preparing formulations for gastrointestinal-targeted therapies
TWI820001B (zh) 2016-05-25 2023-11-01 日商田邊三菱製藥股份有限公司 醫藥組成物的用於製造非思覺失調症病患之負性症狀治療劑的用途
IL319156A (en) 2017-06-21 2025-04-01 Minerva Neurosciences Inc Controlled-release oral dosage forms are resistant to gastric acid.
EP3840835A1 (en) 2018-08-21 2021-06-30 Minerva Neurosciences, Inc. Use of roluperidone to treat negative symptoms and disorders, increase neuroplasticity, and promote neuroprotection
WO2020264486A1 (en) 2019-06-28 2020-12-30 Teva Czech Industries S.R.O Solid state forms of roluperidone and salts thereof
EP4479049B1 (en) 2022-02-14 2025-12-17 Minerva Neurosciences, Inc. Use of roluperidone in preventing relapse in schizophrenia patients

Also Published As

Publication number Publication date
US20250009665A1 (en) 2025-01-09
IL308650A (en) 2024-01-01
JP2020525436A (ja) 2020-08-27
CA3067031A1 (en) 2018-12-27
IL308650B2 (en) 2025-08-01
US12048768B2 (en) 2024-07-30
IL271606A (en) 2020-02-27
RU2020102015A (ru) 2021-07-21
ZA202409847B (en) 2025-09-25
IL308650B1 (en) 2025-04-01
CL2019003743A1 (es) 2020-07-03
CO2019014496A2 (es) 2020-04-01
IL271606B2 (en) 2024-05-01
AU2018290287B2 (en) 2024-06-13
WO2018237207A1 (en) 2018-12-27
US20220401368A1 (en) 2022-12-22
NZ760127A (en) 2026-02-27
IL271606B1 (en) 2024-01-01
RU2020102015A3 (https=) 2021-10-04
BR112019027398A2 (pt) 2020-07-07
MX2023002994A (es) 2023-09-15
UA127349C2 (uk) 2023-07-26
JP2025134828A (ja) 2025-09-17
JP2023175778A (ja) 2023-12-12
PE20200732A1 (es) 2020-07-23
AU2018290287A1 (en) 2020-01-16
US20190038561A1 (en) 2019-02-07
CN111511353A (zh) 2020-08-07
EP3641732A1 (en) 2020-04-29
AU2024219717A1 (en) 2024-10-03
US11464744B2 (en) 2022-10-11

Similar Documents

Publication Publication Date Title
ZA201803101B (en) Oral treatment device
IL261961A (en) Angular dental implant
IL259458A (en) Oral care device
IL271606A (en) Stomach-resistant controlled-release oral dosage forms
PL3335667T3 (pl) Implant dentystyczny
ZA201903101B (en) Pharmaceutical formulations
ZA201605822B (en) Dental implant
ZA201605724B (en) Dental implant
IL266022A (en) Capsule with controlled release
IL258695B (en) Improved implant device
GB201404049D0 (en) Dental implant
DK3229816T3 (en) Proton-bindende polymerer til oral administration
IL248308B (en) Dental Implants
PL3484451T3 (pl) Postać dawkowana
PL3267928T3 (pl) Implant dentystyczny
HUE040495T2 (hu) Fogászati implantációs rendszer
IL262745A (en) Improved preparations containing drugs
GB201609502D0 (en) Dental retaining device
ZA201707739B (en) Dental implant
GB2554471B (en) Dental prosthesis
GB2564114B (en) Release mechanism
PL3348486T3 (pl) Mechanizm zwalniający
IL244188B (en) Angular transfer for dental implants
SG11201710708VA (en) Oral composition
GB201607548D0 (en) Solid dosage form